Edwards Lifesciences — Feb 10, 2026 release

Highlights and Outlook • Q4 sales grew 13.3% to $1.57 billion 1 , constant currency 2 sales grew 11.6% • Q4 TAVR sales grew 12.0% to $1.16 billion 1 ; constant currency 2 sales grew 10.6% • Q4 TMTT sales grew more than 40% to $156 million 1 from repair and replacement therapies • Q4 EPS of $0.11 1 ; adjusted 2 EPS of $0.58 • FY 2025 sales grew 11.5% , 10.7% constant currency 2 • Increased confidence in FY 2026 constant currency 2 sales growth of 8 – 10% • FY 2026 revenue outlook includes TMTT growing 35 – 45% to $740 – $780 million • Increased confidence in FY 2026 adjusted 2 EPS $2.90 – $3.05 “Edwards’ strong fourth quarter and full year performance in 2025 reflect our differentiated strategy with a clear vision around three key elements: focusing solely on structural heart, solving large, urgent and very complex patient needs, and pursuing unique opportunities to innovate and lead, all achieved through excellent execution by our deeply experienced teams,” said Bernard Zovighian, Edwards’ CEO. “Based on multiple catalysts and the company’s strong fourth quarter performance, we have increased confidence in our outlook for 2026 and believe that our 70 years of expertise in valve innovation and world-class evidence will create sustainable growth and expanded profitability. “These enduring catalysts benefitting Edwards in 2026 and the years ahead include distinguished long-term results unique to Edwards from the PARTNER 3 7-year and PARTNER 2 10-year trials, the impact of the practice-changing EARLY TAVR trial, new guidelines for treating aortic stenosis patients in Europe and the approvals of the first transcatheter mitral replacement therapy. We expect additional meaningful catalysts later in 2026 to fuel sus